ST6GALNAC4

Across TCGA pan-cancer cohorts, ST6GALNAC4 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ST6GALNAC4’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ST6GALNAC4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ST6GALNAC4 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

LIHC, BLCA, and LUAD are the cancer types where ST6GALNAC4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ST6GALNAC4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.549	<.001	9	view →
BLCA	All	IV	−0.937	.003	8	view →
LUAD	All	II,III,IV	−0.658	<.001	7	view →
THCA	All	All	+0.389	<.001	7	view →
LUSC	Male	II,III,IV	−1.013	<.001	6	view →
UCEC	All	II,III,IV	−0.992	<.001	6	view →
STAD	All	II,III,IV	+0.933	<.001	6	view →
CHOL	All	All	+2.718	<.001	5	view →
BRCA	All	III,IV	+0.567	.006	5	view →
KICH	All	All	−0.741	<.001	4	view →
PRAD	All	All	−1.417	<.001	2	view →
ESCA	All	All	+1.238	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ST6GALNAC4–LIHC

Open the LIHC breakdown →